Showing results (231-240 of 250) with videos related to

Sort By:
Pageof 25
Nature|January 25, 2019
Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluidAlexandra M Miller, Ronak H Shah, Elena I Pentsova, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|September 14, 2013
Central nervous system cancersLouis Burt Nabors, Mario Ammirati, Philip J Bierman, et al.
Neuro-Oncology Practice|May 11, 2026
Outcomes of inpatient chemoradiotherapy for patients with newly diagnosed glioblastoma and significant functional impairmentNeil Sielski, Anne S Reiner, William E Rosa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 18, 2006
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08Patrick Y Wen, W K Alfred Yung, Kathleen R Lamborn, et al.
Neuro-Oncology|June 4, 2011
International retrospective study of over 1000 adults with anaplastic oligodendroglial tumorsAndrew B Lassman, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Neuro-Oncology|June 5, 2012
Initial treatment patterns over time for anaplastic oligodendroglial tumorsKatherine S Panageas, Fabio M Iwamoto, Timothy F Cloughesy, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 2, 2014
Central nervous system cancers, version 2.2014. Featured updates to the NCCN GuidelinesLouis Burt Nabors, Jana Portnow, Mario Ammirati, et al.
The Oncologist|April 17, 2026
Characterization and Clinical Management of Adverse Events Following Treatment with Repotrectinib: A TRIDENT-1 AnalysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
The Oncologist|May 8, 2026
Characterization and clinical management of adverse events following treatment with repotrectinib: a TRIDENT-1 analysisAlexander Drilon, Byoung Chul Cho, D Ross Camidge, et al.
Pageof 25